Day April 1, 2026

HMN 2026: How FDA-approved compound promotes neuroprotective effects in Parkinson’s disease

NALL improves dopamine-dependent motor learning impairments in LRRK2R1441C mice. Credit: Journal of Clinical Investigation (2026). DOI: 10.1172/jci196137 Northwestern Medicine scientists have discovered that an FDA-approved compound promotes neuroprotective effects in experimental models of Parkinson’s disease. The compound, N-acetyl-L-leucine (NALL), simultaneously…